Abu Dhabi’s government licensed the world’s first state-designated Healthy Longevity Medicine Center in October 2024. The decision marked a regulatory shift toward treating aging as a medical condition, not an inevitable consequence of life. It reflects growing interest in longevity medicine, where researchers and private clinics are betting that they can measure, influence and potentially slow biological aging before disease appears.
The emerging sector raises basic questions about healthcare’s future: Should medicine extend healthy years through targeted interventions, or stick with its traditional disease-by-disease approach? And who decides which treatments deserve insurance coverage, when longevity clinics promise results without strong clinical evidence?
The Science Behind the Shift
Daniel Belsky, associate professor of epidemiology at the Columbia University Mailman School of Public Health and the Robert N. Butler Columbia Aging Center, says the research remains preliminary. “We don’t know yet whether we can really do this. But we do have an alignment of evidence to argue this is possible. And we now have a mobilization of resources to actually test it,” he said.
The idea is to target biological processes that drive several age-related diseases at once. Nir Barzilai, director of the institute for aging research at Albert Einstein College of Medicine in New York City, puts it plainly: “Aging has biology. This biology drives diseases.” Instead of treating diabetes, cardiovascular disease and cancer as separate conditions, medicine could eventually address the shared aging mechanisms that predispose people to all three.
Laboratory studies support the idea. Belsky noted that medicines, exercise, calorie restriction and other interventions can slow the buildup of cellular changes associated with aging and extend animals’ lives, from roundworms to mice. But a major caveat remains. “For humans, we do not yet have clinical trial evidence that intervention on this biology to extend health span is possible,” he said. “But — and this is where I think the excitement comes from — we are seeing the ground shift in advancing toward those human clinical trials.”
One promising line of research looks at epigenetics: changes in how genes are regulated without altering the underlying DNA sequence. Belsky’s Finding Aging Biomarkers by Searching Existing Trials (FAST) project gathers multi-omic data, including proteins, metabolites and epigenetic marks on white blood cells. The team aims to identify biomarkers that respond to interventions and could measure effects on aging biology.
The Clinic Business Model
Longevity clinics have already entered the commercial market. They offer conventional medical assessments alongside broader testing intended to map a person’s health. Mayo Clinic launched its Healthy Longevity Clinic three years ago as of September 30, 2026. Singapore’s National University Health System has established a similar program, pairing detailed assessment with personalized lifestyle or medical interventions.
Abu Dhabi’s regulatory framework, introduced 1 year elapsed as of September 30, 2026, is the first global attempt to standardize the young field. The Department of Health defined a clinical category and set standards for longevity medicine facilities. Allan Boston, chief operating officer of the Institute for Healthier Living Abu Dhabi—licensed as the world’s first state-designated specialized Healthy Longevity Medicine Center—described the market’s appeal: “All your cells are aging constantly. In the past, we thought that was just an inevitable stage of life. It’s not inevitable. There are things we can now start to do about that. That changes the whole concept of medicine.”
He added, “The more we understand that cellular level activity, the more we can design therapies, drugs, other immunotherapies, technologies that can alter that pathway, slow it down and even potentially reverse it.”
The Evidence Gap
One major question remains open. Belsky acknowledged that “the connection between changing those biomarkers and extending healthy lifespan has not been established.” It could take decades to see outcomes. A trial testing whether an intervention started at age 40 or 50 prevents chronic disease might need to follow participants for two or three decades.
Researchers are studying whether aging biomarkers can predict longer-term outcomes and act as “surrogate endpoints” in clinical trials—that is, whether biomarker changes can stand in for actual disease prevention. If validated, this approach could speed regulatory approval and attract investment. But it could also encourage clinics and companies to sell interventions based on biomarker changes alone, without proof that they extend healthy lifespan.
Some scientists have already warned that the field needs better regulation as longevity clinics spread. Abu Dhabi’s licensing framework addresses the concern, but most jurisdictions still lack that oversight.
What Actually Works Today
Belsky urged a practical view. Sleep, exercise, community and diet can influence the biology of aging without advanced medical innovations or specialist clinics. “The thing we know works is available in some form to most of us,” he said. “These are things where almost all of us can make progress. We can add healthy years to our lifespan even without these new drugs.”
Why This Matters:
Longevity medicine brings both opportunity and risk. Private investment and innovation can speed scientific progress without burdening taxpayers—a real advantage. Yet clinics are expanding faster than the clinical evidence. Those charging substantial fees for biomarker testing and personalized interventions rely on promises that remain unproven. Regulators must support innovation while protecting consumers from expensive treatments without demonstrated benefit.
The central challenge is to advance aging biology research rigorously while stopping premature commercialization of findings. Abu Dhabi’s regulatory approach offers one model, but most markets remain unregulated. If longevity interventions prove effective and costly, questions about equity and insurance coverage will also arise, potentially driving major healthcare policy debates in coming years.